Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IQVIA HoldingsLTS:0JDM +1.58%86 Forward Rate of Return (Yacktman) % is 14.67% as of Jun. 2026, which is 20% below its 10-year median of 18.30. GuruFocus rates LTS:0JDM with a GF Score™ of 86/100 and a GF Value™ of $248.35 (Fairly Valued). The stock has 8 warning signs investors should review. Among 92 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 69.57% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. IQVIA Holdings's forward rate of return for was 14.67%.
The historical rank and industry rank for IQVIA Holdings's Forward Rate of Return (Yacktman) % or its related term are showing as below:
LTS:0JDM'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 13.22 Med: 18.3 Max: 23.13
Current: 13.3
During the past 13 years, IQVIA Holdings's highest Forward Rate of Return was 23.13. The lowest was 13.22. And the median was 18.30.
LTS:0JDM's Forward Rate of Return (Yacktman) % is ranked better than 69.57% of 92
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.355
vs LTS:0JDM: 13.30
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
IQVIA Holdings (LTS:0JDM) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
IQVIA Holdings Forward Rate of Return (Yacktman) % Related Terms
IQVIA Holdings Forward Rate of Return (Yacktman) % Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings Forward Rate of Return (Yacktman) % Chart
LTS:0JDM vs A, IDXX, WAT: Forward Rate of Return (Yacktman) % Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings Forward Rate of Return (Yacktman) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's Forward Rate of Return (Yacktman) % falls into.
IQVIA Holdings Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 14.67% mean?
IQVIA Holdings (LTS:0JDM) has a Forward Rate of Return (Yacktman) % of 14.67% as of Jun. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on IQVIA Holdings and its competitors. This is 20% below median its historical median of 18.30. Over the past decade, IQVIA Holdings' Forward Rate of Return (Yacktman) % has ranged from 13.22 to 23.13. According to the industry distribution chart, IQVIA Holdings ranks #28 out of 92 companies in the Medical Diagnostics & Research industry, placing it in the top 30.4%.
Is IQVIA Holdings' Forward Rate of Return (Yacktman) % too high?
IQVIA Holdings' current Forward Rate of Return (Yacktman) % of 14.67% is 20% below median its 10-year median of 18.30. Over the past 10 years, this metric has ranged from a low of 13.22 to a high of 23.13. The Medical Diagnostics & Research industry median Forward Rate of Return (Yacktman) % is 5.36. IQVIA Holdings' value of 14.67% is 173.9% above this industry median. Based on the distribution chart, IQVIA Holdings ranks #28 out of 92 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IQVIA Holdings has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Forward Rate of Return (Yacktman) % compare to A and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #28 out of 92 companies for Forward Rate of Return (Yacktman) %. This puts IQVIA Holdings in the upper half of its industry. The industry median Forward Rate of Return (Yacktman) % is 5.36. IQVIA Holdings' value of 14.67% is 173.9% above this benchmark. Historically, IQVIA Holdings' own Forward Rate of Return (Yacktman) % has ranged from 13.22 to 23.13 over the past decade. While the company's 10-year median is 18.30 vs. the industry median of 5.36, IQVIA Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Medical Diagnostics & Research company?
The median Forward Rate of Return (Yacktman) % among Medical Diagnostics & Research companies is 5.36, based on 92 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current Forward Rate of Return (Yacktman) % of 14.67% is 173.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Forward Rate of Return (Yacktman) % is 5.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current Forward Rate of Return (Yacktman) % is 14.67%, which is 20% below median its own 10-year median of 18.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Fairly Valued. The stock's GF Value™ is $248.35, compared to a current price of $261.68 — trading 5.4% above its estimated fair value. The current Forward Rate of Return (Yacktman) % is 14.67%, which is 20% below median its 10-year median of 18.30 and 173.9% above the Medical Diagnostics & Research industry median of 5.36. IQVIA Holdings' overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current Forward Rate of Return (Yacktman) % is 14.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be overvalued.
The current stock price of $261.68 is trading 5.4% above its estimated GF Value™ of $248.35.
GuruFocus considers IQVIA Holdings to be Fairly Valued.
Key valuation signals for LTS:0JDM:
Forward Rate of Return (Yacktman) %: 14.67% (20% below median its 10-year median of 18.30)
GF Value™: $248.35 vs. price of $261.68 (5.4% above fair value)
Industry Position: 173.9% above the Medical Diagnostics & Research median (#28 of 92)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
86GF Score
Get the complete analysis for LTS:0JDM
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
